The Molecular International Prognostic Scoring System (IPSS-M) has improved the prediction of clinical outcomes for myelodysplastic syndromes (MDS). The Artificial Intelligence Prognostic Scoring System for MDS (AIPSS-MDS), based on classical clinical parameters, has outperformed the IPSS, revised version (IPSS-R). For the first time, we validated the IPSS-M and other molecular prognostic models and compared them with the established IPSS-R and AIPSS-MDS models using data from South American patients.

中文翻译：

---

评估下一代测序时代骨髓增生异常综合征非分子预后系统的相关性。


国际分子预后评分系统 (IPSS-M) 改进了骨髓增生异常综合征 (MDS) 临床结果的预测。基于经典临床参数的 MDS 人工智能预后评分系统 (AIPSS-MDS) 的性能优于 IPSS 修订版 (IPSS-R)。我们首次验证了 IPSS-M 和其他分子预后模型，并将其与使用南美患者数据建立的 IPSS-R 和 AIPSS-MDS 模型进行了比较。